Drugs / EBV-specific cytotoxic T cells
EBV-specific cytotoxic T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01823718 | Feb 2007 → Aug 2014 | lymphoma | Nantes University Hospital | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EBV-specific cytotoxic T cells | “T-cell therapy using a bank of EBV-specific cytotoxic T cells: lessons from a phase I/II feasibility and safety study.” PMID 24598452 ↗ Apr 2014 |
| Known as | EBV-CTLs | “We report herein the results we obtained and the limitations we experienced during the production and use of a bank of Epstein-Barr virus (EBV)-transformed human cytotoxic T...” PMID 24598452 ↗ Apr 2014 |
| Known as | EBV-transformed human cytotoxic T lymphocytes | “We report herein the results we obtained and the limitations we experienced during the production and use of a bank of Epstein-Barr virus (EBV)-transformed human cytotoxic T...” PMID 24598452 ↗ Apr 2014 |
| Modality | Cell therapy | “T-cell therapy using a bank of EBV-specific cytotoxic T cells” PMID 24598452 ↗ Apr 2014 |